Want to see PDEX full AI Analyst Report?
Top Page
Pro-Dex
(NASDAQ:PDEX)
Select Model
Select Model
Rating:75Outperform
Price Target:
$62.00
▲(12.87% Upside)
Action:Reiterated
Date:05/21/26
The score is driven primarily by solid financial performance with strong recent margins and improving leverage, tempered by inconsistent operating cash-flow conversion. Technicals add support due to a clear uptrend, though overbought signals increase near-term risk. Valuation contributes positively given the low P/E.
Positive Factors
Strong profitability margins
Sustained TTM margins near 16% (net) and 23% (EBITDA) indicate durable pricing power and operational efficiency in precision surgical manufacturing. Those margins support reinvestment, cover fixed costs, and provide a buffer versus cyclical revenue swings, underpinning long-term earnings resilience.
Negative Factors
Inconsistent operating cash conversion
Volatile operating cash conversion—OCF covering only ~50% of net income TTM and prior negative OCF years—signals working-capital timing and collection risks. This inconsistency can force external financing for growth, capex, or to smooth payouts despite reported profitability, raising funding risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong profitability margins
Sustained TTM margins near 16% (net) and 23% (EBITDA) indicate durable pricing power and operational efficiency in precision surgical manufacturing. Those margins support reinvestment, cover fixed costs, and provide a buffer versus cyclical revenue swings, underpinning long-term earnings resilience.
Read all positive factors
Pro-Dex Key Performance Indicators (KPIs)
Any
Revenue by Segment
Highlights revenue from different business segments, revealing which areas are driving growth and which may need strategic adjustments.
Highlights revenue from different business segments, revealing which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyPro-Dex (PDEX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$213.98M
Dividend YieldN/A
Average Volume (3M)29.60K
Price to Earnings (P/E)18.1
Beta (1Y)0.43
Revenue Growth16.39%
EPS Growth29.86%
CountryUS
Employees180
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)3.70
Shares Outstanding3,192,759
10 Day Avg. Volume32,852
30 Day Avg. Volume29,604
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.92
Price to Sales (P/S)2.15
P/FCF Ratio-49.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pro-Dex Business Overview & Revenue Model
Company Description
Pro-Dex, Inc. focuses on the development and manufacturing of advanced motorized surgical instruments. These sophisticated tools are supplied globally to original equipment manufacturers (OEMs) in the medical device sector. Their product portfolio...
How the Company Makes Money
Pro-Dex primarily makes money by providing contract design, development, and manufacturing services for powered surgical device products and components. Revenue is generally generated when customers place orders for manufactured devices/components...
Pro-Dex Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
61
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 74.64M | 66.59M | 53.84M | 46.09M | 42.04M | 42.04M |
| Gross Profit | 20.73M | 19.51M | 14.55M | 12.75M | 13.13M | 13.13M |
| EBITDA | 19.63M | 14.13M | 4.35M | 10.82M | 6.88M | 6.88M |
| Net Income | 12.00M | 8.98M | 2.13M | 7.07M | 4.57M | 4.57M |
Balance Sheet | ||||||
| Total Assets | 74.98M | 61.19M | 52.48M | 51.82M | 49.09M | 49.09M |
| Cash, Cash Equivalents and Short-Term Investments | 10.98M | 7.16M | 6.85M | 4.07M | 1.60M | 1.60M |
| Total Debt | 20.17M | 16.58M | 13.55M | 14.79M | 15.97M | 15.97M |
| Total Liabilities | 29.78M | 24.56M | 21.61M | 20.23M | 23.66M | 23.66M |
| Stockholders Equity | 45.20M | 36.63M | 30.87M | 31.59M | 25.43M | 25.43M |
Cash Flow | ||||||
| Free Cash Flow | 6.97M | -2.93M | 5.22M | 4.49M | -2.52M | -2.52M |
| Operating Cash Flow | 7.34M | -1.68M | 6.20M | 5.46M | -847.00K | -847.00K |
| Investing Cash Flow | 2.72M | -238.00K | -2.23M | -885.00K | -1.24M | -1.24M |
| Financing Cash Flow | -11.23M | -292.00K | -4.27M | -2.49M | -790.00K | -790.00K |
Pro-Dex Technical Analysis
Positive
54.93
Price Trends
61.62
Positive
58.40
Positive
49.11
Positive
Market Momentum
2.21
Negative
61.14
Neutral
84.24
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PDEX, the sentiment is Positive. The current price of 54.93 is below the 20-day moving average (MA) of 61.11, below the 50-day MA of 61.62, and above the 200-day MA of 49.11, indicating a bullish trend. The MACD of 2.21 indicates Negative momentum. The RSI at 61.14 is Neutral, neither overbought nor oversold. The STOCH value of 84.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PDEX.
Pro-Dex Risk Analysis
Pro-Dex disclosed 24 risk factors in its most recent earnings report. Pro-Dex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pro-Dex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $213.98M | 18.11 | 29.10% | ― | 16.39% | 29.86% | |
73 Outperform | $226.05M | 22.05 | 8.74% | 1.84% | -7.00% | -12.28% | |
60 Neutral | $156.98M | -86.73 | -10.63% | ― | 22.41% | 60.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PDEX
Pro-Dex
67.02
22.92
51.97%
UTMD
Utah Medical Products
71.00
14.97
26.72%
MBOT
Microbot Medical
1.55
-1.53
-49.68%
KRMD
REPRO-MED Systems
3.40
-0.81
-19.24%
ZJYL
Jin Medical International Ltd.
3.38
-8.82
-72.28%
Pro-Dex Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Pro-Dex Issues Updated Investor Presentation Under Regulation FD
Neutral
Jun 17, 2026
On June 17, 2026, Pro-Dex, Inc. began delivering an investor presentation to analysts and institutional investors, aligning the materials with its existing SEC filings and prior public disclosures. The presentation, which may be updated or modifie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.